Man Claims He Lost 132 Pounds by Eating At This Famous Fast Food Restaurant Every Day
Nowadays, it's become commonplace to view fast food as the unhealthiest option for a potential meal. But in a surprising development for the culinary community, a 32-year-old Rhode Island resident is now claiming to have lost 132 pounds from a predominantly fast food-centric eating regimen.
In an exclusive interview with Eat This, Not That, digital content producer Tom Carroll said that he shed a shocking amount of weight from eating at Chick-fil-A every day for 14 months.
"Back before I was on my health journey, I would have never thought of a fast food restaurant as something that would be my engine for losing weight," Carroll admitted. But by ordering the right options off Chick-fil-A's menu, Carroll experienced a massive change in his physical health.
So what is this magic menu item that Carroll ultimately helped lose so much weight? Per Carroll's interview, the 32-year-old revealed that he specifically ordered the Spicy Southwest Salad every day, even going so far to order it a day in advance to prepare for Chick-fil-A's closure on Sundays. At 680 calories, it's one of the restaurant's healthiest meal options, complete with a hearty supply of protein in every bite.
"I was always completely conscious of the fact that all the fast food I was eating was keeping me from being healthy," said Carroll. "When I thought 'health foods,' fast food was the furthest thing from my mind. But when it finally clicked for me that this salad from Chick-fil-A was not only healthy, but also fun, easy and delicious just like the burgers and tacos I had been eating my whole adult life, it immediately changed my perception of what fast food could be."
By choosing to visit Chick-fil-A so often, Carroll has credited the restaurant for drastically improving his overall quality of life, sentiments he further echoes in his informative essay "Chick-fil-A Saved My Life." Additionally, Carroll has said that strategically cutting out certain foods and beverages like alcoholic drinks significantly helped him cut back on his weight, viewing it as one of the best things he did for his diet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Deadly fungus tied to a pharaoh's tomb may help fight cancer
When you buy through links on our articles, Future and its syndication partners may earn a commission. A fatal fungus once thought to be a curse could potentially help fight disease. Scientists discovered molecules in a fungus linked to Tutankhamun's tomb that stop the proliferation of cancer cells and are as effective as currently used treatments. Fungi may hold a treasure trove of medical breakthroughs just waiting to be unearthed. The "pharaoh's curse" fungus, Aspergillus flavus, can be used to fight leukemia, according to a study published in the journal Nature Chemical Biology. The fungus is called "pharaoh's curse" because it is "linked to the deaths of several archeologists who opened ancient tombs around the world, including the famous discovery of the Tomb of Tutankhamun in the 1920s," said Popular Mechanics. At the time, many believed the deaths to be the result of an ancient curse rather than fungal inhalation. Aspergillus flavus is known as a "microbial villain," said Popular Science. It is "one of the most frequently isolated mold species in both agriculture and medicine," and is "commonly found in soil and can infect a broad range of important agricultural crops." Exposure to the fungus can lead to lung infections, especially in those who are immunocompromised. Despite its deadly reputation, the fungus contains a class of peptides that can fight cancer when modified. Researchers were able to isolate four molecules from A. flavus, which they named "asperigimycins." The molecules were capable of forming a unique structure of interlocking rings. "Even without genetic modifications, the asperigimycins demonstrated medical potential when mixed together with human cancer cells," said Popular Science. "Two out of the four variants had potent effects against leukemia cells." When fatty molecules called lipids were added to the mix, the asperigimycins were as effective as the FDA-approved drugs used to treat the cancer. There also seem to be no apparent side effects from A. flavus. Asperigimycins are part of a class of molecules called ribosomally synthesized and post-translationally modified peptides, or RiPPs. A number of them have been found in bacteria, but they are "rare in fungi and notoriously hard to study," said Wired. This is "mainly because no one was looking closely until now." However, "even though only a few have been found, almost all of them have strong bioactivity," Qiuyue Nie, a postdoctoral fellow at the University of Pennsylvania and an author of the study, said in a statement. "This is an unexplored region with tremendous potential." Fungi have long been a source of medicine, perhaps most famously the antibiotic penicillin. This research implies there is more where that came from. "Nature has given us this incredible pharmacy," Sherry Gao, an associate professor at UPenn and the senior author of the study, said in the statement. "It's up to us to uncover its secrets. As engineers, we're excited to keep exploring, learning from nature and using that knowledge to design better solutions." The next step in the process will be to test the newly discovered treatment on animals and then eventually on humans. It will likely still be many years before the treatments can be widely used on people.
New York Post
2 days ago
- New York Post
Semen allergy is real — and often misdiagnosed. Here are the troubling signs
This is nuts! For a small but suffering contingent of women, an allergy to semen is seriously interfering with intimacy. A semen allergy, also known as seminal plasma hypersensitivity (SPH), is a rare reaction to proteins found in male spermatic fluid, according to the Cleveland Clinic. 4 A semen allergy, also known as seminal plasma hypersensitivity (SPH), is a rare allergic reaction to proteins found in male spermatic fluid. doucefleur – SPH is recognized as a Type 1 hypersensitivity, characterized by a rapid, exaggerated immune response to an allergen, putting semen in the same category as peanuts and pet dander. For those afflicted, reactions to exposure to ejaculate run the gamut from burning, itching, redness and swelling of the vulva or vagina to hives, shortness of breath, dizziness and even anaphylaxis. One Colorado college student with SPH reported that oral sex led to inflammation and temporary facial paralysis. She said that the severity of the side effects depends on the quantity of sperm she's encountered. Experts believe the condition, which can be life-threatening if there's anaphylaxis, is underreported. SPH was first documented in 1967, when a woman was hospitalized following a 'violent allergic reaction' to sex. For the next three decades, it was assumed that SPH affected fewer than 100 women worldwide. Yet, a 1997 study led by allergist Jonathan Bernstein revealed that nearly 12% of reported postcoital symptoms could be classified as SPH. 4 SPH does not directly cause infertility, but it can make conception challenging. nito – In 2013, Michael Carroll, an associate professor in reproductive science, conducted a small, unpublished survey that found a similar rate. However, he maintains that the true number may be much higher. 'Many cases go unreported, misdiagnosed or dismissed as STIs, yeast infections or general 'sensitivity,' ' Carroll wrote this week in The Conversation. 'A 2024 study reinforced this finding, suggesting that SPH is both more common and more commonly misdiagnosed than previously believed.' This condition is now believed to affect one in 40,000 people. Experts maintain that the main allergen is not sperm cells themselves, but prostate-specific antigen (PSA) in seminal plasma. 4 While condoms mitigate the risk of allergen exposure to PSA, for some unlucky lovers, allergies to semen and condoms make intimacy particularly challenging. Pixel-Shot – Interestingly, there appears to be cross-reactivity. Carroll notes that Can f 5, a protein found in dog dander, is structurally similar to human PSA, meaning that women allergic to dogs may have a higher likelihood of experiencing an allergic reaction to semen. It is also possible to be exposed to an allergen through ejaculate. In 2022, OnlyFans star Lucy Banks shared her experience of suffering an allergic reaction to peanuts from her partner's ejaculate. She has since been spreading a warning to others about the dangers of sexually transmitted food allergies — especially from a peanut-loaded penis. Diagnosis of SPH is, of course, made via skin prick. 4 Lucy Banks is warning others to be cautious of sexually transmitted food allergies after her own experience. Instagram/ @itsnotlucybanks While condoms mitigate the risk of allergen exposure to PSA, for some unlucky lovers, allergies to semen and condoms make intimacy particularly troublesome. SPH does not directly cause infertility, though conception can be challenging. Treatments for would-be parents include antihistamine medication before intercourse, anti-inflammatories after and/or desensitization therapy using diluted seminal plasma. In cases where the allergic reaction is severe, some couples turn to IVF using washed sperm free from seminal plasma to divert the allergic trigger. In rare instances, men can be allergic to semen. Known as post-orgasmic illness syndrome (POIS), the condition is characterized by extreme fatigue, weakness, a fever or sweating, mood changes or irritability, problems concentrating, a stuffy nose and itching eyes following intercourse. These symptoms can occur within seconds, minutes or even a few hours after ejaculation — and they can last from two to seven days. POIS was first documented in 2002, and more than 50 cases have been recorded worldwide. However, experts believe that, similar to SPH, the actual incidence rate could be even higher. Believed to be an autoimmune response or allergic reaction, POIS is also diagnosed via skin testing.
Business Wire
2 days ago
- Business Wire
A2 Bio Announces First Patient Dosed in DENALI-1 Phase 1/2 Clinical Study of A2B395, a Novel Allogeneic Precision CAR T Cell Therapy for Patients with Solid Tumors that Express EGFR
AGOURA HILLS, Calif.--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced dosing of the first patient in the DENALI-1 (NCT06682793) clinical study. DENALI-1 is a multicenter phase 1/2 dose-escalation clinical study to evaluate the safety and efficacy of A2B395, an allogeneic logic-gated CAR T cell therapy, in participants with solid tumors that express EGFR and have lost HLA-A*02 expression. A2B395 is the first allogeneic therapy utilizing the A2 Bio Tmod™ technology platform to advance into clinical development. 'Dosing of the first patient in DENALI-1 is a key milestone toward providing a precise, novel 'off the shelf' CAR T cell therapy for patients with solid tumors that express EGFR. No curative therapies are available for people living with these cancers." Share A2 Bio is advancing A2B395 as a potential new precision cell therapy in participants with solid tumors that express EGFR, including colorectal cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and renal cell carcinoma. 'Dosing of the first patient in DENALI-1 is a key milestone toward providing a precise, novel 'off the shelf' CAR T cell therapy for patients with solid tumors that express EGFR. No curative therapies are available for people living with these cancers, and current treatments can be toxic, debilitating, and fatal. All of us at A2 Bio are grateful to the patients, investigators, and clinical care providers participating in DENALI-1,' said John Welch, M.D., Ph.D, interim chief medical officer of A2 Bio. Significant unmet needs remain for people living with EGFR-positive cancers, despite recent advances that have produced new targeted therapies, antibody-based therapies, and immunotherapies. 1,2 In the recurrent unresectable, locally advanced, or metastatic setting, the intent of standard of care treatment is typically palliative rather than curative, and has not changed significantly in several decades. Precision medicine enables efficient identification of patients in the A2 Bio clinical studies. Patients are enrolled in DENALI-1 through BASECAMP-1 (NCT04981119), a master prescreening study that identifies patients with HLA loss of heterozygosity (LOH) at any time in the course of their disease via next-generation sequencing. Upon disease progression, the participant may screen for enrollment in DENALI-1. There is no time requirement between the studies, and patients may go directly from BASECAMP-1 to DENALI-1 based on their own disease course. BASECAMP-1 utilizes artificial intelligence (AI)-enabled precision diagnostics as a cost-effective, high-yield approach to identify eligible patients for all A2 Bio clinical studies. 3, 4 In addition to A2B395, A2 Bio continues to advance its clinical development of A2B694, the BASECAMP-1 prescreening study, as well as other preclinical programs as the company pursues additional pipeline expansion opportunities using its proprietary Tmod™ technology platform. The Tmod™ platform comprises a suite of technologies that can be used in isolation or in combination, and in both autologous and allogeneic settings, to create novel therapies for various cancers and beyond. The Tmod™ platform utilizes a dual-receptor design consisting of an activator that targets tumor cells and a blocker that protects normal cells. This dual-receptor design is intended to provide selective killing of tumor tissues that express EGFR and have lost the HLA-A*02 gene permanently. This novel design is aimed at tackling the fundamental challenge in solid tumor cancer medicines – the ability to selectively kill tumor cells and protect normal cells. About DENALI-1 DENALI-1 (NCT06682793) is a phase 1/2, open-label, nonrandomized study evaluating the safety and efficacy of A2B395 in adults. Patients are enrolled through BASECAMP-1 (NCT04981119), a master prescreening study that identifies patients with HLA LOH at any time in the course of their disease via next-generation sequencing. Upon disease progression the participant may screen for enrollment in DENALI-1. More information about DENALI-1 and clinical trial sites participating in the study are available on the A2 Bio clinical trials website. About the Tmod™ Platform A2 Bio has pioneered a precision-targeting cellular system – the Tmod™ platform – that incorporates two receptors, an activator and a blocker, to aim the powerful armaments of immune cells directly at tumors to unequivocally differentiate tumors from normal tissues. The activator recognizes antigens on tumor cells that trigger their destruction, while the blocker recognizes antigens on normal cells that protect them. This novel blocker technology enables precise, personalized and effective T cell targeting. The blocker component equips Tmod™ cells with the capacity to identify tumors as distinct from normal cells. About A2 Bio A2 Biotherapeutics, Inc. (A2 Bio) is a clinical-stage biotech company developing first-in-class logic-gated cell therapies to address the high unmet need in cancers. A2 Bio invented the proprietary Tmod™ cell therapy platform to tackle the fundamental challenge in cancer treatment—the ability of cancer medicines to distinguish between tumor and normal cells. For more information, please visit the company's website at References: 1 Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):203-18; quiz 19-20. 2 Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med. 2021;27(1):34-44. 3 Smith CJ, Simeone DM, Grierson PM, et al. Improving ethnic and racial diversity in biomarker-driven clinical trials: a proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH). ASCO Annual Meeting 2024. Available at: 4 Lozac'hmeur A, Danek T, Yang Q, et al. Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities. NPJ Precis Oncol. 2024;8(1):174.
